Goldline Pharmaceutical Lists at ₹59.75, Up 32.02%

Goldline Pharmaceutical Ltd, engaged in marketing pharmaceutical products under "Goldline" brand offering 146 products across five segments (Goldline Pharma, Cardinal, Aayushman, InLife, Wellness) catering to physicians, orthopedics, ENT, diabetologists, cardiologists, pediatricians, critical care consultants, and oncology supportive care, made a strong debut on BSE SME on Tuesday, May 19, 2026. The Goldline Pharmaceutical share price opened at ₹59.75 representing premium of 38.95% from issue price of ₹43.00, touched high of ₹60.00 (up 39.53%) before hitting lower circuit at ₹56.77 (up 32.02%).

Goldline Pharmaceutical Listing Details

Goldline Pharmaceutical launched its fresh issue IPO at ₹43 per share with minimum investment of 6,000 shares costing ₹2,58,000 raising ₹11.61 crore including ₹3.15 crore from anchor investors. The IPO received phenomenal response with extraordinary subscription of 840.74 times - retail investors at 881.15 times, NII massively subscribed at 1,662.04 times, QIB at 180.22 times.

First-Day Trading Performance

Listing Price: Goldline Pharmaceutical stock price opened at ₹59.75 representing premium of 38.95% from issue price, touched high of ₹60.00 (up 39.53%) before hitting lower circuit at ₹56.77 (up 32.02%), with VWAP at ₹59.27. The strong listing delivered healthy gains for IPO investors with turnover of ₹5.63 crore, traded volume of 9.51 lakh shares, delivery of 100%, and market capitalisation of ₹54.50 crore against pre-IPO market cap of ₹41.28 crore.

Growth Drivers and Challenges

Growth Drivers

Diversified Product Portfolio: 146 products across five segments covering multiple medical specialties including physicians, diabetologists, cardiologists, pediatricians, critical care, and oncology supportive care providing diversified revenue streams.

Consistent Revenue Growth: Revenue growing from ₹19.85 crore in FY23 to ₹28.06 crore in FY25, PAT growing from ₹0.26 crore to ₹2.83 crore (10x growth), healthy ROCE of 24.22% and ROE of 21.02%.

Challenges

Third-Party Manufacturing Dependence: Fully dependent on third-party suppliers for all products raising major concerns over quality control, supply continuity, and margin sustainability.

Leveraged Balance Sheet: Debt-to-equity ratio of 1.07 with borrowings of ₹9.47 crore against net worth of ₹12.36 crore, bulk of IPO proceeds (₹8.35 crore) going towards debt repayment.

Utilisation of IPO Proceeds

Debt Repayment: ₹8.35 crore for prepayment/repayment of outstanding borrowings representing bulk of proceeds to deleverage balance sheet.

General Corporate Purposes: ₹1.71 crore for general corporate purposes.

Financial Performance

Revenue: ₹21.41 crore for 9 months ended December 2025 (below run-rate of full FY25), ₹28.06 crore for FY25, growth from ₹23.57 crore in FY24 and ₹19.85 crore in FY23.

Net Profit: ₹2.22 crore for 9 months FY26, ₹2.83 crore in FY25, growth from ₹1.81 crore in FY24 and ₹0.26 crore in FY23, with post-IPO EPS of ₹3.09 and P/E of 13.93x. Investors tracking Goldline Pharmaceutical share price should note PAT margin of 10.38% and EBITDA margin of 19.41%.

Stay informed with the upcoming IPOs, subscriptions, and listing updates.